Compare Expensify Inc (EXFY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expensify Inc vs Neurocrine Biosciences Inc — how do they compare? Expensify Inc trades at $2.4 (market cap $209.73M), while Neurocrine Biosciences Inc trades at $152.5 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 78.5× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| EXFY | NBIX | |
|---|---|---|
Market Cap | $209.73M | $16.46B |
Sector | Technology | Health |
52-Week High | $2.69 | $185.50 |
52-Week Low | $0.75 | $123.10 |
Enterprise Value | $149.35M | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
